The optimal therapy for patients with relapsed indolent B-cell non-Hodgkin's lymphoma is unclear.
Combination chemotherapy such as CHOP (cyclophosphamide. doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use.
However, no comparative studies of these therapies have been reported.
Since relapsed indolent B-cell NHL is generally regarded as incurable with current therapies, the place of each of these therapies is likely to be determined by their relative efficacy, toxicity and cost.
We undertook a literature review and a retrospective analysis of patients receiving combination chemotherapy for relapsed indolent B-cell NHL at our institution to determine the response rates and the duration of response when treated with CHOP or fludarabine.
Reported response rates and median response duration for these regimens are similar, and similar to those reported in phase II studies of rituximab.
A cost minimization analysis was therefore conducted.
The per patient costs for the treatment of drug-related adverse events were £5049 for CHOP, £295 for fludarabine and £109 for rituximab.
When costs of a full course of each treatment were compared, the costs per patient for CHOP, fludarabine and rituximab were £7210 (£5975-8445). £10022 (£8917-11126) and £6080 (£5892-6267) respectively. (...)
Mots-clés Pascal : Lymphome non hodgkinien, Lymphocyte B, Faible malignité, Cyclophosphamide, Agent alkylant, Anticancéreux, Doxorubicine, Antibiotique, Association médicamenteuse, Vincristine, Antimitotique, Protocole thérapeutique, Fludarabine, Traitement, Rituximab, Anticorps monoclonal, Chimiothérapie, Immunothérapie, Analyse coût, Economie santé, Royaume Uni, Europe, Moutarde à l'azote, Oxazaphosphinane dérivé, Anthracyclines, Etude comparative, Alcaloïde, Récidive, Purine nucléotide, Homme, Hémopathie maligne, Lymphoprolifératif syndrome, Protocole CHOP
Mots-clés Pascal anglais : Non Hodgkin lymphoma, B-Lymphocyte, Low malignancy, Cyclophosphamide, Alkylating agent, Antineoplastic agent, Doxorubicin, Antibiotic, Drug combination, Vincristine, Antimitotic, Therapeutic protocol, Fludarabine, Treatment, Rituximab, Monoclonal antibody, Chemotherapy, Immunotherapy, Cost analysis, Health economy, United Kingdom, Europe, Nitrogen mustard, Oxazaphosphinane derivatives, Anthracyclins, Comparative study, Alkaloid, Relapse, Purine nucleotide, Human, Malignant hemopathy, Lymphoproliferative syndrome
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0396917
Code Inist : 002B02R02. Création : 22/03/2000.